Navigation Links
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Date:12/8/2011

es Litigation Reform Act of 1995.  These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," predict," "opportunity" and "should," among others.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >30 kg/m2), or overweight patients (BMI >27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the t
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
2. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
3. SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
4. Sequel Systems, Inc. Meaningful Use EHR Receives ONC-ATCB 2011/2012 Certification
5. Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology
6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
7. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
10. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
11. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Pranoprofen ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma ... as an inflammatory drug, pranoprofen was later developed ... under the trade name of pranopulin for the ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ) ... on China,s Tobramycin Market, 2010-2019" report to their ... eye drop and ointment are the most common prescription ... caused by eye infection. Currently, dozens of enterprises in ... tobramycin, among which the Top 5 are s.a. Alcon- ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... Champions Oncology, Inc.  ("Champions" or  the ... a company engaged in the development of advanced technology ... of oncology drugs, has appointed Gary G. Gemignani to ... Chief Financial Officer. Joel Ackerman, the Company,s Chief Executive ...
... When it comes to breast cancer, a physician,s ability to ... treatment depends on the quality of information revealed through diagnostic ... most advanced technology in breast cancer detection with positron emission ... scanners in the Chicagoland area. Essentially, PEM is ...
Cached Medicine Technology:Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation 2Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation 3Palos Offers New Technology in the Fight Against Breast Cancer 2
(Date:8/30/2015)... , ... August 30, 2015 , ... ... has been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould ... a proven professional, focused on your goals. Kathleen graduated from Florida State ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris ... college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio ... expand its reach and impact through innovative technologies and strategies. , “I am very ...
(Date:8/29/2015)... Church, VA (PRWEB) , ... August 30, 2015 ... ... **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... much more than a simple digital handwritten signature. , Clinical trial ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, ... improve the lives of patients, according to a newly published report. Surviving Mesothelioma ... the full article. , The authors of the new paper focus on ...
Breaking Medicine News(10 mins):Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2
... Hospitalar LFE 250SX and LFE 200SX to Target ... Bioscience (Nasdaq: PURE ) today announced ... (Lifebio), recently obtained national regulatory approval for its ... LFE 200SX" and "Desinfetante Hospitalar LFE 250SX," which ...
... City-Based Site Pulls Together Extensive State/Local Resources and ... A breakthrough Web solution for families, consumers and ... is now available to all New Yorkers. ... Behavioral Health ( www.nycnetworkofcare.org ) is an online ...
... Alta Bates Summit Medical Center will offer a free skin ... Street, Oakland, CA, 94609. This community cancer screening is supported ... Bay Area non-profit dedicated to changing the face of cancer. ... being diagnosed each year, skin cancer is the most common ...
... Service Corporation (Nasdaq: PRSC ) today announced ... million annual contract to operate a consumer-run adult mental ... contract is being funded through the state,s Mental Health ... home and community based delivery model is very much ...
... Choose Different Approaches, Yet Face Hurdles in Light ... HealthLeaders-InterStudy NASHVILLE, Tenn., Feb. 19 HealthLeaders-InterStudy, ... reports that significant state Medicaid reform efforts in ... in light of the nation,s economic downturn, particularly ...
... 19 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; ... results for the fourth quarter ending December 31, 2008 and ... 2009. Unless specified otherwise, all amounts are in U.S. dollars ... pivotal year for us as we concluded a series of ...
Cached Medicine News:Health News:PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants 2Health News:PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants 3Health News:PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants 4Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 2Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 3Health News:Lazarex Cancer Foundation Sponsors Free Community Skin Cancer Screening at Alta Bates Summit Medical Center 2Health News:Providence Service Corporation California Subsidiary Awarded $1.5 Million Contract Under State's Mental Health Services Act 2Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 2Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 3Health News:QLT Announces Fourth Quarter and Year End 2008 Results 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 3Health News:QLT Announces Fourth Quarter and Year End 2008 Results 4Health News:QLT Announces Fourth Quarter and Year End 2008 Results 5Health News:QLT Announces Fourth Quarter and Year End 2008 Results 6Health News:QLT Announces Fourth Quarter and Year End 2008 Results 7Health News:QLT Announces Fourth Quarter and Year End 2008 Results 8Health News:QLT Announces Fourth Quarter and Year End 2008 Results 9Health News:QLT Announces Fourth Quarter and Year End 2008 Results 10Health News:QLT Announces Fourth Quarter and Year End 2008 Results 11Health News:QLT Announces Fourth Quarter and Year End 2008 Results 12Health News:QLT Announces Fourth Quarter and Year End 2008 Results 13Health News:QLT Announces Fourth Quarter and Year End 2008 Results 14Health News:QLT Announces Fourth Quarter and Year End 2008 Results 15Health News:QLT Announces Fourth Quarter and Year End 2008 Results 16Health News:QLT Announces Fourth Quarter and Year End 2008 Results 17Health News:QLT Announces Fourth Quarter and Year End 2008 Results 18Health News:QLT Announces Fourth Quarter and Year End 2008 Results 19
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: